MontrehTavakkoliMD

UCLA David Geffen SOM, Memorial Sloan-Kettering Cancer Center

Dr. Tavakkoli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 2017 - 2018
David Geffen School of Medicine at UCLAClass of 2017
Columbia UniversityM.A., Biotechnology, > 4.0 G.P.A, 2010 - 2014
University of California, RiversideB.S., Biology, Cum Laude, Chancellor's Honors Award, Dean's Honor, 2004 - 2009

2012 Biomedical Sciences Outstanding Scholar Award UCLA David Geffen SOM, Thomas Haider
Medical Fellowship, 2014-2015 Howard Hughes Medical Institute
Chancellor's Honor List University of California, Riverside
Dean's Honor List University of California, Riverside
Cum Laude University of California, Riverside, 2009
Medical Student Summer Fellowship Program Memorial Sloan-Kettering Cancer Center
Join now to see all

PubMed

6 citations
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali
Journal of Hematology & Oncology. 2023-05-08
100 citations
CD99 is a therapeutic target on disease stem cells in myeloid malignancies.
Stephen S. Chung, William S. Eng, Wenhuo Hu, Mona Khalaj, Francine E. Garrett-Bakelman
Science Translational Medicine. 2017-01-25
4 citations
Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes
Montreh Tavakkoli, Stephen S. Chung, Christopher Y. Park
Expert Opinion on Therapeutic Targets. 2018-04-20

Journal Articles

CD99 is a Therapeutic Target on Disease Stem Cells in Myeloid Malignancies
Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY, Science Translational Medicine, 1/2017
Acute promyelocytic leukemia: where did we start, where are we now, and the future
Coombs CC, Tavakkoli M, Tallman MS, Blood Cancer Journal, 2/2015
Pathogenic MicroRNA's in Myeloid Malignancies
Khalaj M, Tavakkoli M, Stranahan A, Park CY, Frontiers in Genetics, 9/2014
A high resolution gene expression map of the Arabidopsis shoot meristem stem cell niche
Yadav RK, Tavakkoli M, Girke T, Gonehal VR, Development, 12/2013
Survivorship in AYA's with Hematologic Malignancies
Kishtagari A, Tavakkoli M, Oeffinger KC, Park J, Acta Hematologica, 10/2013
WUSCHEL mediates stem cell homeostasis by regulating stem cell number and patterns of cell division and differentiation of stem cell progenitors.
Yadav RK, Tavakkoli M, Gonehal VR, Development, 11/2010
Join now to see all

Abstracts/Posters

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71
Montreh Tavakkoli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD164: A Novel Marker Distinguishing Hematopoeitic Stem/Progenitor Cells (HSPC) from Leukemic Stem Cells
Royston D, Gao Q, Tavakkoli M, Chung SS, Delvin S, Roshal M, Park CY, Laboratory Investigation, 2016
Therapeutic targeting of CD99 in T cell malignancies
Tavakkoli M, Park CY, HHMI Med Fellows Meeting, 5/2015
Targeting CD99 in T-cell neoplasms
Tavakkoli M, Lee DH, Chung SS, Park CY, Proceedings of the American Association for Cancer Research, 3/2015
CD99 is a Potential Therapeutic Target in Non-Hodgkin Lymphoma
Tavakkoli M, Lee DH, Durham B, Feldstein J, Park CY, Laboratory Investigation, 2015
CD99 Is a Therapeutic Target on Disease Initiating Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes
Chung SS, Tavakkoli M, Klimek V, Park CY, Blood, 12/2014
CD99 Is a Therapeutic Target On Disease Stem Cells In Acute Myeloid Leukemia and The Myelodysplastic Syndromes
Chung SS, Tavakkoli M, Devlin SM, Park CY, ASH, Ernest N. Morial Convention Center, New Orleans, LA, 12/1/2013
The Therapeutic Targeting of CD99 Mediates CD99 Clustering and Cytoskeletal Rearrangements in Acute Myeloid Leukemia
Tavakkoli M, Chung SS, Park CY, MSKCC Medical Student Summer Fellowship Poster Presentation, Memorial Hospital, NYC, NY, 7/2012
Join now to see all

HHMI Medical Fellows Ambassador at UCLA, Howard Hughes Medical Institute, Med Fellows Program 2015 - Present
Program Regional Co-Chair, Howard Hughes Medical Institute, Med Fellows Program 2014 - 2015
U.S. Advisor, Community Health Practice Internship at UNAN-Managua 2013 - 2014

Memorial Sloan Kettering Cancer Center, Graduate Medical Education (GME) Extern*Worked in the outpatient leukemia clinic with Martin S. Tallman, MD and Aaron Viny, MD *Wrote a review *Studied the toxicity profile of chimeric-antigen receptor (CAR) therapy in patients with ALL in ongoing clinical trials; helped develop the MSK ALL database; PIs: Jae Park, MD & Dan Douer, MD2014 - 2015
Howard Hughes Medical Institute, Medical FellowPrimary research focus was on identifying a biomarker on patient samples and cell lines, therapeutically targeting this marker with monoclonal antibodies, and identifying the mechanism of cytotoxicity and therapeutic window. This is an independent project that I initiated in the lab2014 - 2015
Memorial Sloan Kettering Cancer Center, InternStudied the mechanism of cytotoxicity mediated by an immunotherapeutic agent targeting a novel cell surface marker, CD99, on leukemic stem cells in AML2013 - 2014
NIH-Memorial Sloan Kettering Cancer Center Medical Student Summer FellowUtilized fluorescence microscopy to study the immuno-therapeutic targeting of leukemic stem cells in AML cell lines; developed an extensive protocol for immunofluorescence microscopy currently used by members of the laboratory2012 - 2012
UCR, Undergraduate Researcher2008 - 2010